---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-034982"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:09:33.468166+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# INmune Bio raises ~$4.8M in registered direct offering with warrants at 10% premium

## Summary
- Gross proceeds ~$4.8M from sale of 571,592 shares and warrants at $8.32 per unit.
- Warrant exercise price $9.152 (10% premium); warrants accelerate upon positive Phase 2 Alzheimer's top-line data.
- Officers, directors, employees bought ~20% of offering at $8.445 per unit.
- Net proceeds to fund Phase 2 Alzheimer's trial (XPro1595) and Phase 1 prostate cancer trial (INKmune).
- Offering expected to close April 24, 2024; LifeSci Capital as sole placement agent.

## SEC filing metadata
- accession: 0001213900-24-034982
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/0001213900-24-034982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/ea0204329-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-034982
- JSON: https://secwatch.observer/filing/0001213900-24-034982.json
- Plain text: https://secwatch.observer/filing/0001213900-24-034982.txt

## Key facts
- Material Agreements
  Inmune Bio, Inc. entered into Placement Agency Agreement with LifeSci Capital LLC valued at Cash fee equal to 4% of gross proceeds from sale of shares and warrants (effective 2024-04-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: LifeSci Capital LLC
  - Value: Cash fee equal to 4% of gross proceeds from sale of shares and warrants
  - Effective: 2024-04-19
  source text: Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 19, 2024, between the Company and LifeSci Capital LLC (the “Placement Agent Agreement,” the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/0001213900-24-034982-index.htm
- Material Agreements
  Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran (effective 2024-04-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Purchasers
  - Value: 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran
  - Effective: 2024-04-19
  source text: On April 19, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on the signature page thereto (the “Purchasers”) for the purchase and sale of an aggregate of 571,592 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 571,592 shares of its common stock (“Warrants”) in a registered direct offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024034982/0001213900-24-034982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.